CompletedPhase 3NCT03855280
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medexus Pharma, Inc.
- Principal Investigator
- Khaled MohamedMedexus Pharma, Inc.
- Intervention
- APVO101(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 11 years · All sexes
- Timeline
- 2020 – 2022
Study locations (11)
- Centro Estadual de Hemopterapia e Hematologia do Espirito Santo, Vitória, Espírito Santo, Brazil
- Universidade Estadual de Campinas - Centro de Hematologia e Hemoterapia, Campinas, Brazil
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil
- JSC K Eristavi National Center for Experimental and Clinical Surgery, Tbilisi, Georgia
- PMSI Institute of Mother and Child, Chisinau, Moldova
- Worthwhile Clinical Trials, Lakeview Hospital, Benoni, Gauteng, South Africa
- Haemophilia Comprehensive Care Centre, Johannesburg, South Africa
- Cukurova University School of Medicine, Adana, Turkey (Türkiye)
- Ege University School ofMedicine, Izmir, Turkey (Türkiye)
- National Specialized Children's Hospital OKHMATDYT, Kyiv, Ukraine
- State Institute: Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine, Lviv, Ukraine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03855280 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China